前列舒通与α受体阻滞剂对前列腺炎NIH-CPSI评分、临床治疗效果及安全性分析  

Analysis of NIH-CPSI score, clinical efficacy and safety of prostate cancer patients treated with prostaglandin E and alpha blockers

作　　者：易虎[1] 赵明[1] 何锦华[1] 

机构地区：[1]天津中医药大学第一附属医院泌尿外科

出　　处：《中国生化药物杂志》2017年第5期234-236,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的探讨前列舒通与α受体阻滞剂对前列腺炎NIH-CPSI评分、临床治疗效果的影响。方法回顾性分析2015年3月~2016年8月在天津中医药大学第一附属医院治疗的前列腺炎患者的临床资料,根据其治疗方式分为对照组和观察组,对照组给予前列舒通治疗,观察组给予前列舒通与α受体阻滞剂联合治疗。观察2组患者的治疗效果,比较2组患者治疗前后NIH-CPSI评分、前列腺液常规、细胞因子水平和不良反应的差别。结果观察组治疗的有效率为97.78%,明显高于对照组（85.00%）,差异有统计学意义（χ~2=4.575,P=0.032）;2组患者治疗前NIH-CPSI评分无差别,治疗后,观察组疼痛或不适、排尿症状、生活质量和总分均低于对照组（P〈0.05）;2组患者治疗前前列腺液常规无差别,治疗后,观察组卵磷脂小体高于对照组,白细胞均数低于对照组（P〈0.05）;2组患者治疗前细胞因子水平无差别,治疗后,观察组TNF-α、IL-6水平低于对照组（P〈0.05）;2组患者在治疗期间均无明显肝、肾功能损伤等不良反应发生,具有较好的安全性。结论前列舒通联合α受体阻滞剂对前列腺炎有较好的治疗效果,可明显改善临床症状,具有良好的应用价值。Objective To investigate the effect of the treatment of prostatitis and NIH-CPSI score and clinical therapeutic effect of prostate cancer treated with prostaglandin E and alpha blockers.MethodsThe clinical data of patients with prostatitis treated in The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine from March 2015 to August 2016 in were retrospectively analyzed.The patients were divided into control group and observation group.The control group was treated with the treatment of the first aid, while the observation group was treated with the combination of the first and the second.The therapeutic effects of the two groups were observed and compared between the two groups before and after treatment NIH-CPSI score, prostate fluid routine, cytokine levels and adverse reactions.ResultsIn the observation group, the treatment efficiency was 97.78%, significantly higher than the control group （85%）, the difference was statistically significant （χ2=4.575, P=0.032）;Two groups of patients before treatment NIH-CPSI score no difference, after treatment, the observation group of pain or discomfort, voiding symptoms, quality of life and total score were lower than the control group（P〈0.05）;Two groups of patients before treatment, no difference in the prostatic fluid, after treatment, the observation group was higher than the control group, the number of white blood cells was lower than the control group（P〈0.05）;There was no difference in the levels of cytokines before and after treatment in the two groups.After treatment, the levels of TNF-α, IL-6 in the observation group were lower than those in the control group（P〈0.05）.There were no obvious adverse reactions such as liver and kidney injury during the treatment of two groups of patients.ConclusionThe treatment of prostatitis combined with alpha blocker has good therapeutic effect, can significantly improve the clinical symptoms, and has good application value.

关 键 词：前列舒通 前列腺炎 NIH-CPSI 细胞因子 

分 类 号：R697.33[医药卫生—泌尿科学]